WallStreetZenWallStreetZen

NASDAQ: HALO
Halozyme Therapeutics Inc Earnings Dates, Reports, Calls

OverviewForecastEarnings
RevenueDividendOwnership
Halozyme Therapeutics earnings were $557.3M for the trailing 12 months ending Jun 30, 2025, with 71.6% growth year over year. The latest HALO earnings report on Jun 30, 2025 announced Q2 2025 earnings of $165.2M, up 39.9% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, HALO reported annual earnings of $444.1M, with 57.7% growth.

HALO past earnings growth

How has HALO's earnings growth performed historically?

Company
71.65%
Industry
31.2%
Market
29.26%
HALO's earnings have grown faster... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
HALO's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Market Performance
HALO's earnings growth is accelerating... subscribe to Premium to read more.
Accelerating Earnings Growth Performance

HALO earnings history

Current Revenue
$1.2B
Current Earnings
$557.3M
Current Profit Margin
47.3%

HALO Return on Equity

Current Company
136.6%
Current Industry
-9.6%
Current Market
32.4%
HALO's Return on Equity (136.6%)... subscribe to Premium to read more.
High Return on Equity Performance

HALO undefined

Current Company
26.4%
Current Industry
0%
HALO is generating higher Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when HALO announces earnings.

HALO undefined

Current Company
36.99%
Current Industry
7.8%
HALO has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

HALO vs Biotech Stocks

TickerEBITDAEarningsY/Y EarningsEPS
HALO$791.84M$557.28M+28.37%$4.48
TECH$216.88M$73.40M-20.71%$0.47
ROIV-$432.28M-$490.63MN/A-$0.70
VRNA-$34.62M-$81.19MN/A-$0.96
MDGL-$267.03M-$281.90MN/A-$12.73
View Top Biotech Stocks

Halozyme Therapeutics Earnings Reports & History FAQ

What were Halozyme Therapeutics's earnings last quarter?

On HALO's earnings call on Invalid Date, Halozyme Therapeutics (NASDAQ: HALO) reported Q2 2025 earnings per share (EPS) of $1.36, up 86.3% year over year. Total HALO earnings for the quarter were $165.16 million. In the same quarter last year, Halozyme Therapeutics's earnings per share (EPS) was $0.73.

If you're new to stock investing, here's how to buy Halozyme Therapeutics stock.

Is Halozyme Therapeutics profitable or losing money?

As of the last Halozyme Therapeutics earnings report, Halozyme Therapeutics is currently profitable. Halozyme Therapeutics's net profit (also called net income) for the twelve months ending Jun 30, 2025 was $557.28 million, a 65.22% increase year over year.

What was HALO's earnings growth in the past year?

As of Halozyme Therapeutics's earnings date in Invalid Date, Halozyme Therapeutics's earnings has grown 71.65% year over year. This is 40.44 percentage points higher than the US Biotechnology industry earnings growth rate of 31.2%. HALO earnings in the past year totalled $557.28 million.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.